Yajun Guo

ORCID: 0000-0002-0572-6869
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Bone and Dental Protein Studies
  • RNA Interference and Gene Delivery
  • CAR-T cell therapy research
  • Glycosylation and Glycoproteins Research
  • Immune Cell Function and Interaction
  • vaccines and immunoinformatics approaches
  • T-cell and B-cell Immunology
  • Nanoparticle-Based Drug Delivery
  • Cancer, Hypoxia, and Metabolism
  • Cell Adhesion Molecules Research
  • Lymphoma Diagnosis and Treatment
  • Immune cells in cancer
  • Inflammation biomarkers and pathways
  • HER2/EGFR in Cancer Research
  • Toxin Mechanisms and Immunotoxins
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Bone Metabolism and Diseases
  • Congenital Heart Disease Studies
  • Circular RNAs in diseases
  • Tracheal and airway disorders
  • Cytokine Signaling Pathways and Interactions

Guangxi Medical University
2024

First Affiliated Hospital of GuangXi Medical University
2024

Second Military Medical University
2008-2023

National Engineering Research Center for Nanotechnology
2008-2023

Gansu Agricultural University
2021-2022

China Agricultural University
2022

Second Hospital of Anhui Medical University
2020

Anhui Medical University
2020

Chinese PLA General Hospital
2010-2016

South China University of Technology
2013-2016

Flaviviruses are a group of human pathogenic, enveloped RNA viruses that includes dengue (DENV), yellow fever (YFV), West Nile (WNV), and Japanese encephalitis (JEV) viruses. Cross-reactive antibodies against Flavivirus have been described, but most them generally weakly neutralizing. In this study, novel monoclonal antibody, designated mAb 2A10G6, was determined to broad cross-reactivity with DENV 1–4, YFV, WNV, JEV, TBEV. Phage-display biopanning structure modeling mapped 2A10G6 new...

10.1371/journal.pone.0016059 article EN cc-by PLoS ONE 2011-01-11

TNFα-targeting therapy with the use of drugs Etanercept, Infliximab, and Adalimumab is used in clinical treatment various inflammatory immune diseases. Although all these reagents function to disrupt interaction between TNFα its receptors, investigations showed advantages compared Etanercept Infliximab. However, underlying molecular mechanism action remains unclear. In our previous work, we presented structural data on how Infliximab binds E-F loop functions as a receptor-binding blocker. To...

10.1074/jbc.m113.491530 article EN cc-by Journal of Biological Chemistry 2013-08-14

Chemical androgen deprivation therapy may suppress adaptive immune responses and block the efficacy of immunotherapy.

10.1126/scitranslmed.aad5659 article EN Science Translational Medicine 2016-04-06

Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B produced hybrid that lost their tumorigenicity and became immunogenic. Syngeneic rats injected BERH-2-B resistant to challenge parental cells, established hepatomas were cured by subsequent injection cells. Both CD4 + CD8 essential for the induction protective immunity; however, only required eradication tumors. The generation tumor elicit antitumor immune responses may be a useful strategy cancer immunotherapy.

10.1126/science.7507262 article EN Science 1994-01-28

Expression of osteopontin correlates with tumor progression and metastasis. The mechanisms by which promotes cell survival remain unclear. Here we used short-hairpin RNA-mediated gene silencing to investigate the antitumor effects depletion in hepatocellular carcinoma (HCC).We applied polyethylenimine nanoparticles deliver a RNA for expression HCC cells. Tumorigenicity metastatic potentials cells were studied vitro nude mice. Nuclear factor-kappaB (NF-kappaB) activation was analyzed gel...

10.1053/j.gastro.2008.05.025 article EN cc-by Gastroenterology 2008-05-08

There is an urgent need for improved therapy advanced ovarian carcinoma, which may be met by administering immune-modulatory monoclonal antibodies (mAbs) to generate a tumor-destructive immune response. Using the ID8 mouse cancer model, we investigated therapeutic efficacy of various mAb combinations in mice with intraperitoneal (i.p.) tumor established transplanting 3 × 106 cells 10 days previously. While most tested mAbs were ineffective when given individually or together, data confirm...

10.1371/journal.pone.0084927 article EN cc-by PLoS ONE 2013-12-19

// Lei Cao 1, 2, 5, * , Xiaoyu Fan Wei Jing 3 Yingchao Liang 2 Rui Chen Yingying Liu Minhui Zhu Rongjie Jia Hao Wang Xueguang Zhang 5 Yanyun 1 Xuyu Zhou Jian Zhao 4, 6 Yajun Guo School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, People's Republic China International Joint Cancer Institute, The Second Military Medical 200433, Changhai Hospital, 4 PLA General Hospital Center, Postgraduate Beijing, 100853, Clinical Immunology Laboratory, First Affiliated Suzhou Suzhou, 215007,...

10.18632/oncotarget.3113 article EN Oncotarget 2015-02-25

Hybrid cell vaccination is a new cancer immune therapy approach that aims at recruiting T help for the induction of tumour specific cytolytic immunity. The vaccines are generated by fusion patients' cells with allogeneic MHC class II bearing to combine tumour's antigenicity immunogenicity molecules. Safety and anti-tumour activity this treatment were assessed in clinical trial has yielded one complete partial remission, 5 cases stable disease among 16 patients advanced stage metastatic...

10.1002/(sici)1097-0215(20000301)85:5<618::aid-ijc4>3.0.co;2-z article EN International Journal of Cancer 2000-03-01

CD11c is an antigen receptor predominantly expressed on dendritic cells (DC), to which targeting has been shown induce robust antigen-specific immune responses. To facilitate targeted delivery of tumor antigens DCs, we generated fusion proteins consisting the extracellular domain human HER or its rat homologue neu, fused single-chain fragment variable specific for (scFv(CD11c)-HER2/neu).Induction cellular and humoral responses antitumoral activity admixed with DC-activating CpG...

10.1158/1078-0432.ccr-08-3321 article EN Clinical Cancer Research 2009-07-08

Abstract Objective Osteopontin (OPN) is a proinflammatory protein with critical role in leukocyte migration. Although OPN has been implicated rheumatoid arthritis (RA), its underlying mechanism remains unknown. In this study, we investigated the and molecular of induction 2 key chemokines, monocyte chemoattractant 1 (MCP‐1) macrophage inflammatory 1β (MIP‐1β), RA. Methods Enzyme‐linked immunosorbent assay quantitative polymerase chain reaction were used to determine chemokine expression....

10.1002/art.24625 article EN Arthritis & Rheumatism 2009-06-29

// Guangchao Li 1,* , Likun Zhao Wei 2,4 Kexing Fan Weizhu Qian 3 Sheng Hou 2,3,4 Hao Wang Jianxin Dai Huafeng and Yajun Guo 1,2,3,4 1 School of Bioscience Bioengneering, South China University Technology, Guangzhou, 2 International Joint Cancer Institute, Second Military Medical University, Shanghai, State Key Laboratory Antibody Medicine &amp; Targeting Therapy Shanghai Cell Engineering Antibody, 4 Pharmacy, Liaocheng Liaocheng, Shandong Provence, * These authors contributed equally to the...

10.18632/oncotarget.2135 article EN Oncotarget 2014-06-26

Abstract Acquired aplastic anemia (AA) is a potentially fatal bone marrow (BM) failure syndrome. IFN-γ–producing Th1 CD4+ T cells mediate the immune destruction of hematopoietic cells, and they are central to pathogenesis. However, molecular events that control development BM-destructive remain largely unknown. Ezh2 chromatin-modifying enzyme regulates multiple cellular processes primarily by silencing gene expression. We recently reported crucial for inflammatory cell responses after...

10.4049/jimmunol.1302943 article EN The Journal of Immunology 2014-04-24

BACKGROUND: High expression of CD14(+)HLA-DR-/low myeloid-derived suppressor cells (MDSCs) is correlated with immunosuppressive activity in various cancers, however, no studies have shown a correlation these clinical outcomes small-cell lung cancer (SCLC) patien ts. OBJECTIVE: The purpose the study was to investigate number, frequency and significance MDSCs SCLC patients. METHODS: peripheral blood 42 patients 37 healthy controls analyzed by using flow cytometry. relationships between number...

10.3233/cbm-150473 article EN Cancer Biomarkers 2015-06-02

The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer. However, resistance to is common. Heterodimerization between ErbB2 and other ErbBs may redundantly trigger cell proliferation signals confer resistance. Here, we developed a bispecific using pertuzumab, another ErbB2-specific humanized that binds distinct epitope from trastuzumab. This antibody, denoted as TPL, retained the full binding activities of both parental antibodies exhibited...

10.1158/0008-5472.can-13-0657 article EN Cancer Research 2013-09-18

Abstract Despite the effectiveness of anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in treatment B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination multiple mechanisms, such as complement-dependent cytotoxicity (CDC) apoptotic signaling, underlies therapeutic success mAbs. Unfortunately, all current mAbs effective CDC are relatively inactive signaling cell death vice versa. In this study, we developed two genetically engineered...

10.1158/0008-5472.can-07-6663 article EN Cancer Research 2008-04-01

To test the effects of a novel monoclonal antibody (mAb) against human osteopontin (OPN) in prevention and treatment collagen-induced arthritis (CIA) to elucidate underlying mechanisms these effects.DBA/1J mice immunized with type II collagen induce CIA were monitored assess anti-OPN mAb on clinical severity disease, pathologic changes joints examined histologically. The survival activated T cells from arthritic synovial fluid patients rheumatoid (RA) determined by TUNEL assay or annexin V...

10.1002/art.23490 article EN Arthritis & Rheumatism 2008-06-24

Graft-versus-host disease (GVHD) reflects an exaggerated inflammatory allogeneic T cell response in hosts receiving hematopoietic stem transplantation (HSCT). Inhibition of pan-Notch receptor signaling donor cells causes reduction GVHD. However, which Notch ligand(s) what APCs is important for priming graft-versus-host reaction remains unknown. We demonstrate that δ-like ligand-4 (Dll4) and Dll4-positive (Dll4(high)) dendritic (i-DCs) play roles eliciting responses. Host-type Dll4(high)...

10.4049/jimmunol.1202820 article EN The Journal of Immunology 2013-02-26
Coming Soon ...